Willingness to pay for mortality risk reductions: does latency matter?
From MaRDI portal
Publication:867448
DOI10.1007/S11166-006-9521-0zbMATH Open1281.62221OpenAlexW3124451478MaRDI QIDQ867448FDOQ867448
Nathalie B. Simon, Maureen L. Cropper, Alan J. Krupnick, Anna Alberini
Publication date: 15 February 2007
Published in: Journal of Risk and Uncertainty (Search for Journal in Brave)
Full work available at URL: http://ageconsearch.umn.edu/record/10500
Recommendations
- Effects of disease type and latency on the value of mortality risk
- Social willingness to pay, mortality risks and contingent valuation
- Cancer premiums and latency effects: A risk tradeoff approach for valuing reductions in fatal cancer risks
- Does risk aversion increase the value of mortality risk?
- To be, or not to be, that is the question: An empirical study of the WTP for an increased life expectancy at an advanced age
Mathematical geography and demography (91D20) Applications of statistics to actuarial sciences and financial mathematics (62P05)
Cites Work
- The value of a statistical life: A critical review of market estimates throughout the world
- On the value of changes in life expectancy: Blips versus parametric changes
- Age, health and the willingness to pay for mortality risk reductions: A contingent valuation survey of Ontario residents
- To be, or not to be, that is the question: An empirical study of the WTP for an increased life expectancy at an advanced age
Cited In (7)
- Social willingness to pay, mortality risks and contingent valuation
- Effects of risk and time preference and expected longevity on demand for medical tests
- On consumer preferences and the willingness to pay for term life insurance
- How Much Does the Far Future Matter? A Hierarchical Bayesian Analysis of the Public's Willingness to Mitigate Ecological Impacts of Climate Change
- Does risk aversion increase the value of mortality risk?
- Effects of disease type and latency on the value of mortality risk
- Cancer premiums and latency effects: A risk tradeoff approach for valuing reductions in fatal cancer risks
This page was built for publication: Willingness to pay for mortality risk reductions: does latency matter?
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q867448)
